Please assess the completion status of the following clinical trial:

Trial Title: Study of INT-747 in Patients With Diabetes and Presumed NAFLD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes, defined by the American Diabetes Association (ADA), as one of the following criteria:~* Symptoms of diabetes plus casual plasma glucose concentration \>200 mg/dL (11.1 mmol/L) or~* Fasting plasma glucose \>126 mg/dL (7.0 mmol/L) or~* 2-hour post-load glucose \>200 mg/dL (11.1 mmol/L) during a 75 g oral glucose tolerance test (GTT).~* Presumed NAFLD, defined by one of the following criteria:~* Alanine aminotransferase (ALT) ≥47 U/L for females and ≥56 U/L for males~* Aspartate aminotransferase (AST) ≥47 U/L for females and ≥60 U/L for males~* Enlarged liver (demonstrated by ultrasound or other imaging technique)~* Diagnostic histological findings shown on prior biopsy (in the last 5 years).~Exclusion Criteria:~* Bilirubin \>2 × ULN~* ALT \>155 U/L for females and \>185 U/L for males.~* AST \>155 U/L for females and \>200 U/L for males.~* Patients taking any antidiabetic medications, with the exception of metformin and sulfonylureas. If the HbA1c is \<11%, patients may be enrolled who have been withdrawn from all other diabetic medications as specified in the protocol, at the discretion of the Principal Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 25 mg INT-747 (Type: ACTIVE_COMPARATOR): None
- 50 mg INT-747 (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).